The biopharmaceutical contract manufacturing market is projected to grow at a CAGR of 10% during 2022-2035, claims Roots Analysis

With the advent of novel technologies and rising preference for such therapeutic interventions, biologics have made a significant impact in the pharmaceutical domain, delivering a ground-breaking treatment regimen for a myriad of disease indications.

For additional details, please visit or email [email protected]


Biopharmaceutical Contract Manufacturing Market (Biopharma CDMO) | Industry Analysis | 2035

With over 450 manufacturing facilities and rising biologics demand, biopharmaceutical contract manufacturing market (biopharma CDMO) is expected to grow at nearly 10% CAGR